CCR1: A Key Regulator of Cell-Cell Adhesion and Survival (G1230)
CCR1: A Key Regulator of Cell-Cell Adhesion and Survival
CCR1 (MIP1aR), a protein that belongs to the immunoglobulin superfamily, is a key regulator of cell-cell adhesion and survival in various tissues. It is expressed in a wide range of tissues and cells, including the placenta, mesenchymal tissue, brain, and cancer cells. CCR1 has been implicated in many biological processes, including cell migration, invasion, and metastasis. In addition, it is also a potential drug target in cancer.
The discovery of CCR1 was made by researchers at the University of California, San Francisco (UCSF) in 2005. CCR1 was identified as a new immune-related gene, and its function was soon confirmed. Studies have shown that CCR1 is involved in the development and maintenance of immune tolerance, as well as in the regulation of cell-cell adhesion and survival.
CCR1 is a transmembrane protein that functions as a receptor for several different signaling pathways. It is a critical regulator of the T-cell receptor (TCR), which is responsible for cell recognition and proliferation. CCR1 has been shown to play a role in the regulation of T-cell receptor signaling by controlling the activity of the protein kinase PD-L1.
In addition to its role in T-cell receptor signaling, CCR1 is also involved in the regulation of cell-cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. CCR1 is shown to regulate cell-cell adhesion by controlling the activity of the protein cadherin. This is important for the proper formation of tissues and organs during development and for the maintenance of tissue homeostasis.
CCR1 is also involved in the regulation of cell survival. Studies have shown that CCR1 can promote the survival of cancer cells by controlling the activity of several different signaling pathways. For example, CCR1 has been shown to inhibit the production of reactive oxygen species (ROS) that can damage cellular components and contribute to the development of cancer.
In addition to its role in cell survival, CCR1 is also involved in the regulation of cell migration and invasion. Studies have shown that CCR1 can promote the migration and invasion of cancer cells by controlling the activity of the protein FAK. This is important for the proper spread of cancer cells throughout the body and for the development of new tumors.
The potential drug target for CCR1 is its role in cancer progression. Studies have shown that CCR1 is often overexpressed in cancer cells, and that its overexpression is associated with cancer growth and poor prognosis. Additionally, CCR1 has been shown to promote the development of cancer stem cells, which are a type of cell that can give rise to all different types of cancer.
In conclusion, CCR1 is a protein that plays a critical role in the regulation of cell-cell adhesion, survival, and migration. Its functions are closely related to several key biological processes, including T-cell receptor signaling, cell-cell adhesion, and cancer progression. As a result, CCR1 is an attractive drug target for cancer researchers. Further studies are needed to fully understand the role of CCR1 in cancer biology and to develop effective therapies for this important protein.
Protein Name: C-C Motif Chemokine Receptor 1
Functions: Receptor for a C-C type chemokine. Binds to MIP-1-alpha, MIP-1-delta, RANTES, and MCP-3 and, less efficiently, to MIP-1-beta or MCP-1 and subsequently transduces a signal by increasing the intracellular calcium ions level. Responsible for affecting stem cell proliferation
The "CCR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCR1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5
